Perioperative treatment of hemophilia A patients: Blood group O patients are at risk of bleeding complications

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 3, 2016, Pages 468-478

  Hazendonk, H C A M ^a   Lock, J ^a   Mathot R A A ^b   Meijer, K ^c   Peters, M ^b   Laros van Gorkom, B A P ^d   van der Meer, F J M ^e   Driessens, M H E ^f   Leebeek, F W G ^g   Fijnvandraat, K ^b   Cnossen, M H ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Netherlands Hemophilia Patient Society (NVHP)   (Netherlands)

^g ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ABO blood group system; Factor VIII; Hemophilia A; Perioperative period; Surgery

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8; BLOOD GROUP ABO SYSTEM; COAGULATING AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; BLOOD GROUP O; BODY WEIGHT; CHILD; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPERATIVE BLOOD LOSS; ORTHOPEDIC SURGERY; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD GROUP ABO SYSTEM; BLOOD LOSS, SURGICAL; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPLICATION; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PARENTERAL DRUG ADMINISTRATION; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; PRESCHOOL CHILD; PROCEDURES; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

ABO BLOOD-GROUP SYSTEM; ADULT; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD LOSS, SURGICAL; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FACTOR VIII; HEMOPHILIA A; HUMANS; INFUSIONS, PARENTERAL; LOGISTIC MODELS; MALE; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PERIOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84975687550     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13242     Document Type: Article

References (42)

1. Fijnvandraat K, Cnossen MH, Leebeek FW, Peters M. Diagnosis and management of haemophilia. BMJ 2012; 344: e2707.
2. Collins PW, Blanchette VS, Fischer K, Bjorkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B; rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20.
3. Leebeek FWG, Mauser-Bunschoten EP, eds. Richtlijn Diagnostiek en behandeling van hemofilie en aanverwante hemostasestoornissen. Utrecht: Van Zuiden Communications BV, 2009.
4. Johnson KA, Zhou ZY. Costs of care in hemophilia and possible implications of health care reform. Hematology Am Soc Hematol Educ Program 2011; 2011: 413-8.
5. Schramm W, Berger K. Economics of prophylactic treatment. Haemophilia 2003; 9(Suppl. 1): 111-5.
6. Feldman BM, Aledort L, Bullinger M, Delaney FM, Doria AS, Funk S, Giangrande P, Lundin B, Manco-Johnson M, Miners A, Scriba PC, Srivastava A, Schramm W, Blanchette VS; Second International Prophylaxis Study Group. The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium. Haemophilia 2007; 13: 745-9.
7. Ljung RCR, Knobe K. How to manage invasive procedures in children with haemophilia. Br J Haematol 2012a; 157: 519-28.
8. Srivastava A, Brewer AK, Mauser Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia, eds. Guidelines for the Management of Hemophilia. Montréal, QC: Blackwell Publishing, 2012.
9. Batorova A, Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol 2000; 110: 715-20.
10. Srivastava A. Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia 2001; 7: 117-22.
11. Négrier C, Lienhart A, Meunier S. Surgeries in patients with haemophilia A performed with a continuous infusion of Recombinate. J Thromb Haemost 2003; 1(Suppl. 1): P0829.
12. Dingli D, Gastineau DA, Gilchrist GS, Nichols WL, Wilke JL. Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. Haemophilia 2002; 8: 629-34.
13. Stieltjes N, Altisent C, Auerswald G, Negrier C, Pouzol P, Reynaud J, Roussel-Robert V, Savidge GF, Villar A, Schulman S. Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience. Haemophilia 2004; 10: 452-8.
14. Perez Bianco R, Primiani L, Neme D, Candela M. Continuous infusion of factor VIII for major orthopedic surgery in persons with haemophilia A. Haemophilia 2004; 10(Suppl. 3): P038.
15. Mulcahy R, Walsh M, Scully MF. Retrospective audit of a continuous infusion protocol for haemophilia A at a single haemophilia treatment centre. Haemophilia 2005; 11: 208-15.
16. Bidlingmaier C, Deml MM, Kurnik K. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections. Haemophilia 2006; 12: 212-7.
17. Koshy M, Weiner SJ, Miller ST, Sleeper LA, Vichinsky E, Brown AK, Khakoo Y, Kinney TR. Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Diseases. Blood 1995; 86: 3676-84.
18. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 202-4.
19. Bjorkman S, Oh M, Spotts G, Schroth P, Fritsch S, Ewenstein BM, Casey K, Fischer K, Blanchette VS, Collins PW. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612-8.
20. Klarmann D, Eggert C, Geisen C, Becker S, Seifried E, Klingebiel T, Kreuz W. Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents. Transfusion 2010; 50: 1571-80.
21. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-96.
22. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, Haan E, Kruitwagen CL, Sixma JJ, van den Berg HM. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost 2000; 83: 65-9.
23. Fijnvandraat K, Peters M, ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995; 91: 474-6.
24. Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, Brettler DB, Fukui H, Hilgartner MW, Inwood MJ, Kasper CK, Kernoff PBA, Levine PH, Lusher JM, Mannucci PM, Scharrer I, MacKenzie MA, Pancham N, Kuo HS, Allred RU. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med 1990; 323: 1800-5.
25. Batorova A, Martinowitz U. Continuous infusion of coagulation factors: current opinion. Curr Opin Hematol 2006; 13: 308-15.
26. Sanders YV, Giezenaar MA, Laros-van Gorkom BA, Meijer K, van der Bom JG, Cnossen MH, Nijziel MR, Ypma PF, Fijnvandraat K, Eikenboom J, Mauser-Bunschoten EP, Leebeek FW; WiN study group. von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost 2014; 12: 1066-75.
27. Kahlon A, Grabell J, Tuttle A, Engen D, Hopman W, Lillicrap D, James P. Quantification of perioperative changes in von Willebrand factor and factor VIII during elective orthopaedic surgery in normal individuals. Haemophilia 2013; 19: 758-64.
28. Hermans C, Altisent C, Batorova A, Chambost H, De Moerloose P, Karafoulidou A, Klamroth R, Richards M, White B, Dolan G. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia 2009; 15: 639-58.
29. Hubbard AR, Weller LJ, Bevan SA. A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates. Br J Haematol 2002; 117: 247-8.
30. Hubbard AR, Sands D, Sandberg E, Seitz R, Barrowcliffe TW. A multi-centre collaborative study on the potency estimation of ReFacto. Thromb Haemost 2003; 90: 1088-93.
31. van Moort I, Meijer P, Verbruggen B, Cnossen MH, de Maat MPM. Variation in factor VIII measurement and classification of haemophilia A severity in the ECAT external quality assessment programme. J Thromb Haemost 2015; 13(Suppl.): 2.
32. Aryal KR, Wiseman D, Siriwardena AK, Bolton-Maggs PH, Hay CR, Hill J. General surgery in patients with a bleeding diathesis: how we do it. World J Surg 2011; 35: 2603-10.
33. Ewenstein B, Wong WY, Casey K, Alai M. FVIII administration in surgery. Haemophilia 2011; 17: 828-9.
34. Goldmann G, Holoborodska Y, Oldenburg J, Schaefer N, Hoeller T, Standop J, Kalff JC, Hirner A, Overhaus M. Perioperative management and outcome of general and abdominal surgery in hemophiliacs. Am J Surg 2010; 199: 702-7.
35. Takedani H. Continuous infusion during total joint arthroplasty in Japanese haemophilia A patients: comparison study among two recombinants and one plasma-derived factor VIII. Haemophilia 2010; 16: 740-6.
36. Negrier C, Shapiro A, Berntorp E, Pabinger I, Tarantino M, Retzios A, Schroth P, Ewenstein B. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients. Thromb Haemost 2008; 100: 217-23.
37. Scharrer I; KOGENATE Bayer Study Group. Experience with KOGENATE Bayer in surgical procedures. Haemophilia 2002; 8(Suppl. 2): 15-8.
38. Fernandez E, Perez R, Hernandez A, Tejada P, Arteta M, Ramos JT. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics 2011; 3: 53-72.
39. Krishna P, Lee D. Post-tonsillectomy bleeding: a meta-analysis. Laryngoscope 2001; 111: 1358-61.
40. Bjorkman S, Folkesson A, Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65: 989-98.
41. Carlsson M, Berntorp E, BjöRkman S, Lethagen S, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997; 3: 96-101.
42. Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S; International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.